J
Josemir W. Sander
Researcher at UCL Institute of Neurology
Publications - 705
Citations - 44517
Josemir W. Sander is an academic researcher from UCL Institute of Neurology. The author has contributed to research in topics: Epilepsy & Population. The author has an hindex of 106, co-authored 680 publications receiving 39038 citations. Previous affiliations of Josemir W. Sander include University of Cincinnati & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Ultimate success in epilepsy – the patient's perspective
TL;DR: Clinicians need to understand how individuals perceive their disorder and, where possible, address those factors that adversely affect patient quality of life in order to achieve true treatment success.
Journal ArticleDOI
Adverse Event Monitoring in Lamotrigine Patients: A Pharmacoepidemiologic Study in the United Kingdom
TL;DR: This postmarketing surveillance study of lamotrigine was performed to provide complementary data to large‐scale Prescription–Event Monitoring study with a retrospective case records survey in five tertiary referral epilepsy centres in the United Kingdom.
Journal ArticleDOI
Neuroimaging in epilepsy.
TL;DR: In this paper, the authors integrate imaging and genetic biomarkers to enable personalized epilepsy treatments to detect the seizure onset zone, predicting and preventing deficits from surgery and illuminating mechanisms of epileptogenesis.
Journal ArticleDOI
Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: A single centre evaluation
Jan Novy,Jan Novy,Emanuele Bartolini,Emanuele Bartolini,Emanuele Bartolini,Gail S. Bell,Gail S. Bell,John S. Duncan,John S. Duncan,Josemir W. Sander,Josemir W. Sander +10 more
TL;DR: Retention rates for LCM, when compared to historical controls appear similar to lamotrigine, topiramate, pregabalin, zonisamide, higher than gabapentin, and lower than levetiracetam.
Journal ArticleDOI
Caffeine and seizures: A systematic review and quantitative analysis
TL;DR: Caffeine can increase seizure susceptibility and protect from seizures, depending on the dose, administration type (chronic or acute), and the developmental stage at which caffeine exposure started, in some cases.